InSilico Medicine Cayman TopCo
4.75
USD
-0.18
(-3.72%)
ISIN
KYG4790P1037
CUSIP
G4790P103
Return %
Stock
S&P 500
1Y
- -
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
USD
•
in mil. unless spec.Working Capital
USD
•
in mil. unless spec.Growth Rates
USD
•
in mil. unless spec.Semi-annual Revenue
USD
•
in mil. unless spec.Semi-annual Earnings Per Share
USD
•
in mil. unless spec.Semi-annual Dividends Per Share
USD
•
in mil. unless spec.Company Description
- CEO
- Aleksandrs Zhavoronkov
- Full Time Employees
- 317
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Building 8W, Phase 2 Hong Kong Hong Kong 1506221
- IPO Date
- Dec 30, 2025
- Website
- insilico.com
- Similar Companies
- Business
- I will proceed to generate the company description based on the latest available information.InSilico Medicine Cayman TopCo, Ltd. engages in AI-driven drug discovery and development through its Pharma.AI platform, delivering proprietary preclinical assets and collaborating with partners to advance clinical programs across oncology, immunology, fibrosis, pain, and metabolic diseases. The company generates revenue primarily through out-licensing, milestone receipts, and collaboration agreements with multinational pharmaceutical and biotechnology partners, supported by project-based engagements and milestone-based payments. Headquartered in Hong Kong and listed on the Hong Kong Stock Exchange (ticker 3696.HK), the company operates with a global footprint, deriving most revenue from activities with partners in Asia-Pacific, Europe, and North America, and maintains a broad pipeline of AI-discovered candidates advancing toward clinical development. MANDATORY MAIN PRODUCTS AND SERVICES: AI-driven drug discovery platforms and capabilities under Pharma.AI; proprietary AI-discovered preclinical and IND-enabling drug candidates across therapeutic areas including oncology, immunology, fibrosis, obesity and metabolic diseases, pain, and related indications; out-licensing and collaborative drug discovery and development agreements enabling partner-driven advancement of AI-generated assets; early-stage clinical development support and translational research services; proprietary compounds and candidates advanced to preclinical or clinical milestones; collaboration-based revenue from upfronts, milestones, and tiered royalties upon commercialization. LATEST MAJOR COMPANY CHANGES: Signs of strategic partnerships and collaborations with major pharmaceutical distributors and CMS-type alliances (notably a multi-year oncology collaboration with a large regional player valued at up to hundreds of millions of USD), expansion of AI-driven drug discovery collaborations focused on CNS and autoimmune indications, nomination of AI-discovered candidates for preclinical development, and progression of oncology assets into Phase 1 trials with associated milestone revenues; continued diversification of the asset pipeline through new AI-discovered preclinical candidates and enhanced platform deployment across global partnerships. ADDITIONAL CONTEXT: Industry segment comprises biotechnology and pharmaceutical research and development services leveraging AI for asset discovery and development; targets include cancer, immunology, fibrosis, metabolic diseases, and pain, with potential additional applications in materials, agriculture, and broader life sciences via cross-industry deployment of Pharma.AI; customer base includes multinational pharma companies, regional biotechs, and contract research collaborators; operates primarily from Hong Kong with project-based engagements worldwide, including Asia-Pacific, Europe, and North America; subsidiary relationships are oriented toward financing and governance structures in Cayman Islands entities, with parent company InSilico Medicine, Inc. serving as the technology and platform owner.
Company News
Insilico Medicine Doses First Patient in GENESIS-IPF-3, the World's First Phase III Trial of a Generative AI-Driven Innovative Drug
AI-empowered Pipeline-in-a-drug Option: Insilico Medicine Nominates ISM9077, Potential First-in-class Target Y Inhibitor, as Preclinical Candidate (PCC) for Ocular Diseases, Inflammatory Disorders and Aging